ClinicalTrials.gg
CompletedNCT05332834Updated Sep 27, 2024

A Phase 1 Study of Single and Multiple Intravenous Doses of SM17 in Healthy Subjects

A Phase 1 interventional study of SM17 and Placebo in Asthma, sponsored by SinoMab BioScience Ltd. Completed at 1 site in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-27.

Sponsored by SinoMab BioScience Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2023, 3 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
77
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,695 studies in Asthma with a site in United States — 135 open to participants now, 188 under way, 19 of them phase 3. Asthma · United States.

Enrollment
736th of 1,353
77 · median 100
Started
2022
with 43 others
Phase 1
128 of 1,695
11 open now
Registered
1,478th of 1,695
by date

Among the 1,695 studies in Asthma with a site in United States, this one is the 736th largest by enrollment of the 1,353 interventional ones that give a count, is one of 44 that started in 2022, is one of 128 in phase 1, and was the 1,478th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

135 of the 1,695 studies in Asthma with a site in United States are open now. Recruiting first, the newest first:

130 more — sign in →

All 135 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 19 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,695 studies in Asthma with a site in United States, or all of them as a file.
02

Study summary

This trial is a phase 1, first-in-human, randomized, double-blind, placebo-controlled dose escalation trial following single and multiple doses intravenous administration of SM17.

It aims to evaluate the safety, tolerability, pharmacokinetic characteristics, pharmacodynamic effect and immunogenicity of single and multiple doses of SM17 injection in healthy subjects.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • SM17
04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must fulfill all of the following inclusion criteria to be eligible for participation in the study:

  1. Healthy, adult, male or female* (of non only), 19-55 years of age, inclusive, at the time of consent.

    * Females of non-childbearing potential are defined as follows:

    • Females who have undergone one of the following sterilization procedures at least 6 months prior to the first dosing:

      • Hysteroscopic sterilization.
      • Bilateral tubal ligation or bilateral salpingectomy.
      • Hysterectomy.
      • Bilateral oophorectomy or
    • Females who are with amenorrhea for at least 1 year prior to the first dosing and follicle stimulating hormone (FSH) serum levels consistent with postmenopausal status at the screening visit.
  2. Male subjects must follow protocol specified guidance as described in Section 12.4.5.
  3. (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 at the screening visit.
  4. Is a non-smoker or ex-smoker who has stopped smoking for at least 6 months prior to the screening visit. Ex-smokers will have a history of \<10 cigarettes pack-year.
  5. Medically healthy with no medical history, physical examination, laboratory profiles, vital signs or ECGs (12-lead reporting RR, PR, QRS, and QTcF), as deemed by the PI or designee, at the screening visit and prior to the first dosing, including the following:

    • QTcF interval is ≤460 msec (males) and ≤470 msec (females) and has findings considered normal or not clinically significant by the PI or designee.
  6. Must sign an IRB-approved form (ICF) prior to any study-specific procedures.
  7. Is able to comply with clinic visits and study-related procedures.

Exclusion criteria

Exclusion Criteria:

Subjects must not be enrolled in the study if they meet any of the following criteria:

  1. Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
  2. History or evidence of a disorder (including psychiatric), condition or disease that, in the opinion of the PI or designee would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.
  3. History or current medical conditions, such as myocardial infarction or stroke within the 3 months prior to the screening visit, known cardiac disease, uncontrolled hypertension, and aortic or cerebral aneurysm.
  4. Previously hospitalized for severe acute respiratory syndrome-coronavirus 2 (SARS Cov 2) prior to the screening visit.
  5. Positive polymerase chain reaction test for SARS-CoV-2, either with the absence or presence of the clinical symptoms of COVID 19
  6. Has evidence of any active or suspected bacterial, viral, fungal, or parasitic infections within the past 6 weeks prior to the screening visit (e.g., common cold, viral syndrome, flu-like symptoms). Subject who, in the opinion of the PI or designee, has a high risk of parasitic disease is also excluded.
  7. Has known Type I/II diabetes.
  8. Was vaccinated with live (attenuated) vaccinations within 1 month prior to the first dosing.
  9. History of of any type, (with the exception of successfully treated in situ cervical cancer, or surgically excised non-melanomatous skin cancers) within 5 years prior to the screening visit.
  10. History of any known primary or secondary immunodeficiency disorder.
  11. History or presence of alcohol or drug abuse within the past 2 years prior to the first dosing.
  12. Positive drugs and/or alcohol results at the screening visit or prior to the first dosing. Subject who has consumed alcohol within 48 hours prior to any study visit including the screening visit, will be excluded.
  13. History or presence of or idiosyncratic reaction to protein treatment, medications, any ingredients of SM17 or related compounds.
  14. Female subjects of .
  15. Female subject who is lactating or breastfeeding.
  16. Female subject with a positive pregnancy test at the screening visit.
  17. Has active infection including tuberculosis (TB) (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), (known positive hepatitis B surface antigen [HBsAg] result), virus (HCV), or (HIV) (positive HIV 1/2 antibodies). Subjects with a past or resolved hepatitis B virus infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Subjects positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA).
  18. Uses of any over-the-counter or prescription medications (unless otherwise specified in this protocol) within the 14 days or 5 half-lives (whichever is longer), prior to receiving the first dose of SM17. Acetaminophen (up to 2 g per day) for analgesia, hormone replacement therapy (e.g., estrogen, thyroid), and spermicidal agents will be allowed after first dosing. All herbal or traditional Chinese medicines (e.g., St. John's Wort), within the 14 days prior to receiving the first dose of SM17, and continuing use if applicable, will be reviewed by the PI and the Medical Monitor. Written documentation of this review and acknowledgment is required for subject participation.
  19. Has tattoo(s) or scarring at/or near the site of infusion or any other condition which may interfere with infusion site examination, in the opinion of the PI or designee.
  20. Has been on a diet incompatible with the on study diet, in the opinion of the PI or designee, within the 30 days prior to the first dosing.
  21. Donated blood (including blood products) or experienced loss of blood ≥ 500 mL within 2 months of the screening visit; blood donation or loss of blood ≥ 200 mL within 1 month prior to the screening visit; or plan to donate blood during the study period.
  22. Plasma donation within 7 days prior to the first dosing.
  23. Donated bone marrow within the last 3 months prior to the first dosing.
  24. Will not be available for protocol-required study visits or procedures, to the best of the subject and PI or designee's knowledge.
  25. Has any kind of disorder that, in the opinion of the PI or designee, may compromise the ability of the subject to give written and/or to comply with all required study procedures.
  26. Is unwilling to avoid rigorous exercise for at least 48 hours prior to first dosing.
  27. Is unwilling to avoid caffeinated beverages for at least 4 hours prior to first dosing.
  28. Is receiving or has received any drug (or is currently using an investigational device) within 30 days or 5 half-lives (whichever is longer) prior to the screening visit. The 30-day window (or 5 half-lives) will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to the screening visit of the current study.
  29. Is receiving or has received any biologics within 90 days or until the expected PD effect has returned to baseline (whichever is longer) prior to the screening visit. The 90-day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to the screening visit of the current study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
77 participants (actual)

Study arms

  • Experimental
    Drug SM17

    Peripheral intravenous injection

    Biological: SM17

  • Placebo comparator
    Drug Placebo

    Peripheral intravenous injection

    Other: Placebo

Interventions

  • BiologicalSM17

    Peripheral intravenous injection

  • OtherPlacebo

    Peripheral intravenous injection

06

What researchers measure

Primary outcomes

  1. Part A and Part B: Number of subjects with adverse events

    To evaluate the safety and tolerability of intravenous doses of SM17 in healthy adult subjects.

    Time frame: Until Follow-up (FU) Visit/Early Termination (ET) Visit (14 and 28 days post-last dose)

Secondary outcomes

  1. Pharmacokinetic parameters of SM17 in healthy subjects

    Pharmacokinetic parameters of SM17 in healthy subjects: peak concentration (Cmax)

    Time frame: 0-20 weeks

Other outcomes

  1. Pharmacokinetic parameters of SM17 in healthy subjects

    Pharmacokinetic parameters of SM17 in healthy subjects: elimination half-life (T1/2)

    Time frame: 0-20 weeks

  2. Pharmacokinetic parameters of SM17 in healthy subjects: time to peak (Tmax)

    Time frame: 0-20 weeks

07

Study locations

1 site
  • Celerion Lincoln
    Lincoln, Nebraska 68502, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Sep 2023, 15 months.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 15 months is above that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2022
First posted
Apr 18, 2022
StartActual
Jun 14, 2022
Primary completionActual
Sep 26, 2023
CompletionActual
Sep 26, 2023
Last update
Sep 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05332834
Lead sponsor
SinoMab BioScience Ltd
Responsible party
Sponsor
First posted
Apr 18, 2022
Start date
Jun 14, 2022
Primary completion
Sep 26, 2023
Completion
Sep 26, 2023
Last update
Sep 27, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion